#1 Clinical Trials Search in Europe

Repagermanium

Repagermanium, also known as propagermanium or DMX-200, is a drug currently being studied in clinical trials for various medical conditions. This article explores the ongoing research on repagermanium, focusing on its potential use in treating COVID-19 and kidney-related diseases such as diabetic kidney disease and focal segmental glomerulosclerosis. We’ll examine the safety and effectiveness of this drug in combination with other medications and its potential impact on patients’ health outcomes.

Table of Contents

What is Repagermanium?

Repagermanium is a medication that is currently being studied for its potential benefits in treating various medical conditions. It is also known by several other names, including propagermanium, PPG, and DMX-200[2][3]. This drug is classified as a C-C chemokine receptor type 2 (CCR2) antagonist, which means it works by blocking a specific type of receptor in the body[1].

Conditions Treated with Repagermanium

Repagermanium is being investigated for its potential effectiveness in treating several medical conditions:

  • COVID-19: Researchers are studying how repagermanium, when used in combination with another drug called candesartan, might help patients hospitalized with COVID-19[1].
  • Diabetic Kidney Disease (DKD): This condition affects the kidneys of people with diabetes. Studies are looking at how repagermanium might help patients with DKD who are already taking another medication called irbesartan[2].
  • Focal Segmental Glomerulosclerosis (FSGS): This is a type of kidney disease that causes scarring in parts of the kidney’s filtering units. Repagermanium is being tested in patients with FSGS who are also taking irbesartan[3].

How Repagermanium Works

Repagermanium works as a CCR2 antagonist. To understand this, let’s break it down:

  • CCR2 stands for C-C chemokine receptor type 2. This is a protein found on the surface of certain cells in our body.
  • An antagonist is a substance that blocks or inhibits the action of something else.

By blocking CCR2, repagermanium may help reduce inflammation and protect organs like the kidneys from damage. In the case of COVID-19, it’s thought that this action might help reduce the severity of the illness[1].

Clinical Trials and Research

Several clinical trials are currently underway to study the effects of repagermanium:

  1. CLARITY 2.0 Trial for COVID-19: This study is testing repagermanium in combination with candesartan (an angiotensin receptor blocker) in patients hospitalized with COVID-19. The researchers are looking at how this combination might improve patients’ health status over time[1].
  2. Trial for Diabetic Kidney Disease: This study is examining how repagermanium might help patients with diabetic kidney disease who are already taking irbesartan. They’re particularly interested in how it affects the amount of protein in patients’ urine, which is an indicator of kidney health[2].
  3. Trial for Focal Segmental Glomerulosclerosis: Similar to the diabetic kidney disease study, this trial is looking at how repagermanium might benefit patients with FSGS who are taking irbesartan[3].

Safety and Side Effects

As with any medication, researchers are carefully monitoring the safety of repagermanium. In the clinical trials, they are watching for potential side effects such as:

  • Hypotension (low blood pressure)
  • Hyperkalemia (high levels of potassium in the blood)
  • Changes in liver function
  • Any other serious adverse events[1]

It’s important to note that these potential side effects are being closely monitored in controlled clinical trials. The full safety profile of repagermanium will be better understood as more research is completed.

How Repagermanium is Administered

In the clinical trials, repagermanium is being given as an oral medication. Patients typically take it as a capsule twice daily. For example:

  • In the COVID-19 study, patients receive one 120mg immediate release capsule twice daily for a total daily dose of 240mg[1].
  • In the kidney disease studies, patients take one capsule twice daily for several weeks (12-16 weeks depending on the study)[2][3].

It’s important to remember that repagermanium is still an experimental drug. It should only be taken under the supervision of healthcare professionals as part of a clinical trial. If you’re interested in learning more about these trials or potentially participating, you should discuss this with your doctor.

Aspect Details
Drug Name Repagermanium (also known as propagermanium or DMX-200)
Drug Class C-C chemokine receptor type 2 (CCR2) antagonist
Conditions Studied COVID-19, Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis
Combination Therapy Tested with candesartan (for COVID-19) and irbesartan (for kidney diseases)
Primary Outcomes Clinical Health Score, Albumin/Creatinine Ratio, Safety (Adverse Events)
Secondary Outcomes Glomerular Filtration Rate, Proteinuria, Hospital/ICU admissions, Mortality
Study Design Double-blind, Randomized, Placebo-controlled, Crossover studies
Treatment Duration Varies by study: 12-16 weeks of active treatment
Safety Monitoring Adverse events, blood pressure, kidney function, liver function

FAQ

  • What is repagermanium and what is it being studied for? Repagermanium, also known as propagermanium or DMX-200, is a drug being studied for its potential in treating various conditions. It's currently being investigated for use in COVID-19 treatment and kidney-related diseases such as diabetic kidney disease and focal segmental glomerulosclerosis.
  • How is repagermanium being tested for COVID-19 treatment? In the CLARITY 2.0 trial, repagermanium is being tested in combination with candesartan (an angiotensin receptor blocker) for patients hospitalized with COVID-19. The study aims to evaluate the safety and effectiveness of this dual treatment approach.
  • What are the potential benefits of repagermanium in kidney diseases? Clinical trials are investigating whether repagermanium can help reduce protein levels in urine and improve kidney function in patients with diabetic kidney disease and focal segmental glomerulosclerosis, particularly when used alongside irbesartan.
  • How is the safety of repagermanium being assessed in these trials? The safety of repagermanium is being assessed by monitoring adverse events, symptoms experienced by participants, and specific measures such as blood pressure, potassium levels, and liver function tests.
  • What is the typical structure of these clinical trials involving repagermanium? Many of the trials use a double-blind, randomized, placebo-controlled, crossover design. This means participants receive both repagermanium and a placebo at different times during the study, allowing researchers to compare the effects of the drug to a placebo in the same individual.

Ongoing Clinical Trials on Repagermanium

  • Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Portugal +1

Glossary

  • Repagermanium: Also known as propagermanium or DMX-200, it is a drug being studied for its potential in treating various conditions, including COVID-19 and kidney diseases.
  • CCR2 antagonist: A type of drug that blocks the C-C chemokine receptor type 2, which is involved in inflammatory processes. Repagermanium is a CCR2 antagonist.
  • Angiotensin Receptor Blocker (ARB): A class of drugs that block the action of angiotensin, a hormone that causes blood vessels to narrow. Examples include candesartan and irbesartan.
  • Clinical Health Score: An 8-point scale used to assess the health status of patients, ranging from not hospitalized with no limitations to death.
  • Albumin/Creatinine Ratio (ACR): A urine test that compares the amount of albumin (a protein) to creatinine. It's used to detect kidney disease and monitor kidney function.
  • Glomerular Filtration Rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • Diabetic Kidney Disease (DKD): A complication of diabetes that affects the kidneys, potentially leading to kidney failure.
  • Focal Segmental Glomerulosclerosis (FSGS): A type of kidney disease characterized by scarring in parts of the kidney's filtering units (glomeruli).
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney disease.
  • Crossover study: A type of clinical trial where participants receive different treatments at different times, allowing each participant to serve as their own control.

References

  1. https://clinicaltrials.gov/study/NCT05122182
  2. https://clinicaltrials.gov/study/NCT03627715
  3. https://clinicaltrials.gov/study/NCT03649152